Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from IDT Australia Limited ( (AU:IDT) ).
IDT Australia Limited has announced the resignation of its CEO, Mr. Paul McDonald, with Mr. Mark Simari stepping in as Executive Chair to ensure business continuity. Despite a 40.6% increase in revenue to $19.9 million for FY25, the company reported a net loss of $7.5 million, partly due to bad debts. The company remains committed to its transformation program and will conduct a comprehensive review of its operations under new leadership to restore profitability.
More about IDT Australia Limited
IDT Australia Limited is a pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The company specializes in the development and production of high potency and high containment pharmaceutical products for both local and international clients. Their facilities are cGMP compliant and regularly audited by the US FDA and Australian TGA, offering services in new drug development, scale-up, and commercial active drug manufacturing, including various oral and injectable finished drug dose forms.
Average Trading Volume: 139,705
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$37.14M
For an in-depth examination of IDT stock, go to TipRanks’ Overview page.